VRTX - CIK 0000875320
The table below shows VERTEX PHARMACEUTICALS INC / MA's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $3.63B | -$492.60M | $3.54B | $4.13B | $2.64B | $3.25B |
| Capital expenditure | $437.60M | $297.70M | $200.40M | $204.70M | $235.00M | $259.80M |
| Investing cash flow | -$945.40M | -$3.77B | -$3.14B | -$321.10M | -$340.90M | $99.40M |
| Dividends paid | - | - | - | - | - |
VERTEX PHARMACEUTICALS INC / MA reported operating cash flow of $3.63B for fiscal year 2025. That is up 837.2% from -$492.60M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from $236.10M (FY 2016) to $3.63B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | $2.02B | $1.18B | $427.60M | $0.00 | $1.43B | $539.10M |
| Financing cash flow | -$2.26B | -$1.49B | -$562.20M | -$67.70M | -$1.48B | -$505.30M |